Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium
- PMID: 20374256
- DOI: 10.1111/j.1440-1681.2010.05387.x
Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium
Abstract
1. The endothelium is critical in the control of vascular haemodynamics and haemostasis. Endothelial dysfunction, typically characterized by decreased nitric oxide bioavailability and response to endothelium-dependent agonists, is well accepted as a defining characteristic of early atherosclerosis. 2. Numerous epidemiological studies have reported that increased levels of circulating HDL are vasculoprotective and reduce the incidence of adverse cardiovascular events. Traditionally, these effects have been attributed to the ability of HDL to remove cholesterol from cells via reverse cholesterol transport. However, there is increasing evidence that the beneficial effects on the endothelium by HDL encompass its anti-inflammatory, antithrombotic and anti-oxidative properties, which include the release of nitric oxide (NO). 3. This review highlights recent findings on the importance of HDL in reducing atherosclerotic risk. We focus on the beneficial effects of HDL-induced NO release and how this relates to endothelial dysfunction and on the effect of HDL on vascular repair via endothelial progenitor cells.
Similar articles
-
HDL slowing down endothelial progenitor cells senescence: a novel anti-atherogenic property of HDL.Med Hypotheses. 2008;70(2):338-42. doi: 10.1016/j.mehy.2007.05.025. Epub 2007 Jul 20. Med Hypotheses. 2008. PMID: 17640824
-
High-density lipoproteins, inflammation and oxidative stress.Clin Sci (Lond). 2009 Jan;116(2):87-98. doi: 10.1042/CS20080106. Clin Sci (Lond). 2009. PMID: 19076062 Review.
-
Multiple actions of high-density lipoprotein.Curr Opin Cardiol. 2008 Jul;23(4):370-8. doi: 10.1097/HCO.0b013e3283043806. Curr Opin Cardiol. 2008. PMID: 18520722 Review.
-
Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids.Trends Cardiovasc Med. 2005 Oct;15(7):265-71. doi: 10.1016/j.tcm.2005.08.005. Trends Cardiovasc Med. 2005. PMID: 16226682 Review.
-
Endothelial and antithrombotic actions of HDL.Circ Res. 2006 Jun 9;98(11):1352-64. doi: 10.1161/01.RES.0000225982.01988.93. Circ Res. 2006. PMID: 16763172 Review.
Cited by
-
Postprandial decrease in LDL-cholesterol in men with metabolic syndrome.Open Med (Wars). 2015 Feb 3;10(1):138-151. doi: 10.1515/med-2015-0025. eCollection 2015. Open Med (Wars). 2015. PMID: 28352689 Free PMC article.
-
High density lipoprotein and cardiovascular diseases.World J Cardiol. 2013 Jul 26;5(7):210-4. doi: 10.4330/wjc.v5.i7.210. World J Cardiol. 2013. PMID: 23888190 Free PMC article.
-
Inhibition of Vascular Inflammation by Apolipoprotein A-IV.Front Cardiovasc Med. 2022 Jun 30;9:901408. doi: 10.3389/fcvm.2022.901408. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35845068 Free PMC article. Review.
-
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Vasc Health Risk Manag. 2013;9:617-70. doi: 10.2147/VHRM.S37119. Epub 2013 Oct 21. Vasc Health Risk Manag. 2013. PMID: 24174878 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical